SCHEMBL3593980

SCHEMBL3593980

CN(C)C1Cc2c(N)cccc2NC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 4/20 0.35
BRD4 O60885 5/20 0.33
CREBBP Q92793 4/20 0.33
DDB1 Q16531 3/20 0.33
CRBN Q96SW2 3/20 0.33
PARP1 P09874 2/20 0.33
BRPF1 P55201 1/20 0.33
TNF P01375 1/20 0.33
IL1B P01584 1/20 0.33
IKZF1 Q13422 1/20 0.33
IKZF3 Q9UKT9 1/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR7 P34969 1/20 0.33
HTR3A P46098 1/20 0.33
OPRM1 P35372 1/20 0.31
OPRL1 P41146 1/20 0.31
EP300 Q09472 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3595541 0.84 HSP90AA1 (0.35) HTR5ABRD4CREBBPDDB1CRBN
SCHEMBL3598950 0.84 ALDH1A1 (0.34) HTR5ABRD4DDB1CRBNTNF
SCHEMBL3593976 0.83 CREBBP (0.34) BRD4CREBBPDDB1CRBNPARP1
SCHEMBL3592386 0.83 TRPV1 (0.38) HTR5ACREBBPDDB1CRBNHTR1A
SCHEMBL3584557 0.83 DDB1 (0.37) HTR5ABRD4CREBBPDDB1CRBN
SCHEMBL3590436 0.81 TRPV1 (0.40) DDB1CRBNHTR1AHTR2AOPRM1
SCHEMBL27746212 0.78 PARP1 (0.37) HTR5ABRD4CREBBPDDB1CRBN
SCHEMBL7484149 0.77 DDB1 (0.33) HTR5ABRD4CREBBPDDB1CRBN
SCHEMBL1450613 0.76 PARP1 (0.36) HTR5ABRD4CREBBPDDB1CRBN
SCHEMBL3596677 0.76 CRBN (0.33) HTR5ABRD4CREBBPDDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 HTR5A 2037/4885BRD4 706/4885CREBBP 2015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.